Baylis Medical’s Cardiology Business Sold to Boston Scientific

A landmark transaction in the medical technology sector

Boston Scientific Corporation has completed the acquisition of the cardiology business of Baylis Medical Company Inc. for an upfront payment of $2.1 billion, subject to customary closing adjustments.

This cross-border transaction reflects ongoing consolidation in the life sciences and medical device industry, where innovation, regulatory considerations and global commercialization strategies intersect.

BCF Business Law advised Baylis Medical throughout this transaction.

Accelerating global adoption of Canadian innovation

By transferring its cardiology business to a global player, Baylis Medical positions its technologies for expanded international reach.

Boston Scientific’s global footprint is expected to accelerate the adoption of key cardiology solutions developed in Canada, including:

• the NRG Transseptal Platform
• the VersaCross Transseptal Platform
• a full suite of transseptal sheaths and dilators
• ventricular tachycardia solutions

This transaction illustrates a common strategic path in the sector: leveraging cross-border M&A to scale innovation beyond domestic markets.

Strategic repositioning and continued investment in Canada

Following the transaction, Baylis Medical will continue to invest in its remaining operations, particularly through its affiliate, Baylis Medical Technologies, which is not part of the sale and remains a separate entity.

This type of carve-out transaction allows companies to:

• unlock value from a specific business unit
• refocus on core growth areas
• reinvest in innovation and R&D
• maintain a strong presence in their home market

For Canadian life sciences companies, it also highlights how partnerships with global players can coexist with continued domestic investment.

Transaction structure and timeline

The transaction was subject to customary closing conditions and regulatory approvals, with both parties operating independently prior to closing to ensure a smooth integration.

No disruption to existing customers was anticipated as part of the transition.

Key considerations in cross-border life sciences transactions

This transaction underscores several legal and business considerations typical of cross-border deals in the medical technology sector:

• Regulatory compliance across multiple jurisdictions
• Intellectual property transfer and protection
• Commercial agreements and licensing frameworks
• Integration planning and operational continuity
• Risk allocation through purchase price adjustments and conditions precedent

These elements are central to structuring transactions that both protect value and enable growth.

BCF’s involvement

BCF advised Baylis Medical with a multidisciplinary team including:

Gino Martel, Annie Gauthier, Sabrina Brosseau-Malo, Olivier Moreau-Notebaert, Thomas Champagne, Marc-André Godard, Jean-François Reed, Nancy Boyle, Kevin Vincelette, Richard Epstein, Eleonora Eusepi, Tuba Yamaç, Jean-Sébastien Brière, Jyoti Chakraborty and Emilia Stoute.

BCF worked in collaboration with Cooley LLP.

Read the press release : Boston Scientific Closes Acquisition of Baylis Medical Company Inc.